He talks about Kymera's dosing methodology, and recaps the data from a degradation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.

He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in...

He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.

He gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has...

Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement.